CN116159086A - 一种抑菌消炎止痒中药乳膏及其制备方法 - Google Patents
一种抑菌消炎止痒中药乳膏及其制备方法 Download PDFInfo
- Publication number
- CN116159086A CN116159086A CN202211075614.7A CN202211075614A CN116159086A CN 116159086 A CN116159086 A CN 116159086A CN 202211075614 A CN202211075614 A CN 202211075614A CN 116159086 A CN116159086 A CN 116159086A
- Authority
- CN
- China
- Prior art keywords
- parts
- water
- extract
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 230000001139 anti-pruritic effect Effects 0.000 title claims abstract description 23
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 25
- 239000003908 antipruritic agent Substances 0.000 title claims description 20
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 16
- 208000003251 Pruritus Diseases 0.000 claims abstract description 51
- 235000015398 thunder god vine Nutrition 0.000 claims abstract description 31
- 241000830536 Tripterygium wilfordii Species 0.000 claims abstract description 30
- 230000007803 itching Effects 0.000 claims abstract description 30
- 241000218682 Pseudolarix amabilis Species 0.000 claims abstract description 27
- 241000758794 Asarum Species 0.000 claims abstract description 24
- 239000006071 cream Substances 0.000 claims abstract description 23
- 241000408747 Lepomis gibbosus Species 0.000 claims abstract description 22
- 235000020236 pumpkin seed Nutrition 0.000 claims abstract description 22
- 235000005206 Hibiscus Nutrition 0.000 claims abstract description 16
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims abstract description 16
- 244000130592 Hibiscus syriacus Species 0.000 claims abstract description 12
- 235000018081 Hibiscus syriacus Nutrition 0.000 claims abstract description 12
- 206010061218 Inflammation Diseases 0.000 claims abstract description 11
- 230000004054 inflammatory process Effects 0.000 claims abstract description 11
- 230000003467 diminishing effect Effects 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 229940092309 pumpkin seed extract Drugs 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 76
- 238000001914 filtration Methods 0.000 claims description 44
- 238000010992 reflux Methods 0.000 claims description 20
- 238000002791 soaking Methods 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 16
- 241000218033 Hibiscus Species 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- -1 polyoxyethylene Polymers 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004519 grease Substances 0.000 claims description 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 235000013871 bee wax Nutrition 0.000 claims description 4
- 239000012166 beeswax Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 150000002191 fatty alcohols Chemical class 0.000 claims description 4
- 229940057995 liquid paraffin Drugs 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 claims description 3
- 239000004166 Lanolin Substances 0.000 claims description 3
- 229960001777 castor oil Drugs 0.000 claims description 3
- 229940074928 isopropyl myristate Drugs 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- 229940039717 lanolin Drugs 0.000 claims description 3
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 229940099259 vaseline Drugs 0.000 claims description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000284380 Hibiscus rosa sinensis Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- 241000264877 Hippospongia communis Species 0.000 description 17
- 201000004624 Dermatitis Diseases 0.000 description 12
- 208000010668 atopic eczema Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000749 insecticidal effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000006748 scratching Methods 0.000 description 3
- 230000002393 scratching effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229960004979 fampridine Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000004706 scrotum Anatomy 0.000 description 2
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960000699 terbinafine hydrochloride Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种抑菌消炎止痒中药乳膏,属于中药技术领域。该中药乳膏剂包括如下重量份组分:雷公藤提取液1~5份、蜂房提取液3~10份、细辛提取液8~20份、木槿皮5~15份、土荆皮3~10份、南瓜子15~30份。本发明采用特定的提取方法获得的雷公藤提取液、蜂房提取液和细辛提取液与木槿皮、土荆皮和南瓜子提取液协同增效,抑菌止痒效果显著,短时间即可见效,且无副作用。
Description
技术领域
本发明涉及中药技术领域,具体涉及一种抑菌消炎止痒中药乳膏及其制备方法。
背景技术
皮肤瘙痒有生理性和病理性两种情况。生理性多是因为空气寒冷干燥所造成的干痒,病理性多是因为免疫力下降所造成的慢性荨麻疹,或者其他类皮肤疾病。皮炎性湿疹是一种常见的由多种内外因素引起的表皮及真皮浅层的炎症性皮肤病,其特点为自觉剧烈瘙痒,皮损多形性,对称分布,有渗出倾向,慢性病程,易反复发作;常见于面部、耳后、四肢屈侧、乳房、手部、阴囊等处,对称分布;根据皮损特点可分为急性、亚急性和慢性湿疹。三者并无明显界限,可以相互转变。另外,外界因素也会导致皮肤瘙痒,比如蚊虫叮咬、食物过敏等,然而皮肤瘙痒经抓挠后必然会出现红肿,甚至流血,导致炎症的发生。
目前,针对皮肤瘙痒或者炎症性皮肤病的治疗药物较多,激素类药物涂抹后有显著改善,但是长期使用会产生依赖性,使人体发胖,产生骨质疏松,对儿童的生长发育有抑制作用;中药类涂抹药物参差不齐,药效差距较大,尤其在止痒效果方面并不显著,多数中药类涂抹膏剂婴幼儿不可使用。故研发一种可任何群体使用、且抑菌消炎止痒效果显著的中药乳膏剂是现阶段急需解决的问题。
发明内容
本发明的目的在于提供一种抑菌消炎止痒中药乳膏及其制备方法,该中药乳膏抑菌止痒效果显著,短时间即可见效,且无副作用。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种抑菌消炎止痒中药乳膏,包括如下重量份组分:雷公藤提取液1~5份、蜂房提取液3~10份、细辛提取液8~20份、木槿皮5~15份、土荆皮3~10份、南瓜子15~30份。
优选地,雷公藤提取液2~4份、蜂房提取液5~8份、细辛提取液10~15份、木槿皮8~10份、土荆皮5~8份、南瓜子20~25份。
优选地,所述雷公藤提取液的制备方法包括如下步骤:称取雷公藤粗粉,用75~95%的乙醇浸泡20~60min,回流提取3次;第一次加5~15倍水量,提取0.5~2.5h,过滤;第二次加5~15倍水量,提取0.5~2.5h,过滤;第三次加2~8倍水量,提取0.5~1.0h,过滤;合并三次过滤液,减压浓缩至初始体积的1/10~1/2,得雷公藤提取液。
优选地,所述蜂房提取液的制备方法包括如下步骤:称取蜂房,于85~100℃加热水煎煮提取3次,第一次加10~25倍量水,提取1~3h,过滤;第二次加10~25倍量水,提取1~3h,过滤;第三次加5~10倍量水,提取0.5~1h,过滤,合并三次过滤液,减压浓缩至初始体积的1/10~1/2,得蜂房提取液。
优选地,所述细辛提取液的制备方法包括如下步骤:称取细辛粉末,加水回流提取3次;第一次加5~15倍水量浸泡1.5~2.5h,回流提取2~4h,过滤;第二次加5~15倍水量浸泡1.5~2.5h,回流提取2~4h,过滤;第三次加2~8倍水量浸泡0.5~1.5h,回流提取1~2h,过滤;合并三次过滤液,减压浓缩至初始体积的1/10~1/2,得细辛提取液。
优选地,所述木槿皮、土荆皮和南瓜子的处理方法包括:按照所述重量份比例称取木槿皮、土荆皮和南瓜子,混合粉碎,用5~15倍量的水浸泡20~60min,文火煎煮1~4h,过滤;于滤渣中加入5~15倍量的水,文火煎煮0.5~2.5h,过滤;合并两次过滤液,减压浓缩至初始体积的1/10~1/2,得木槿皮、土荆皮和南瓜子的提取液。
本发明提供了一种抑菌消炎止痒中药乳膏的制备方法,包括如下步骤:
(1)将1~10份乳化剂、5~40份油脂置于干燥烧杯内,恒温水浴加热至70~90℃,使全部溶解成油相,备用;
(2)将2~10份甘油、20~80份纯化水置另一烧杯中混匀成水相,恒温水浴加热至70~90℃,备用;
(3)将油相缓缓加入水相中,搅拌均匀,均质3~15分钟,冷却降温即得乳膏基质;
(4)按照所述重量份将雷公藤提取液,蜂房提取液,细辛提取液,木槿皮、土荆皮和南瓜子的提取液加入乳膏基质中,混合均匀,即得抑菌消炎止痒中药乳膏。
优选的,所述乳化剂包括但不限于单硬脂酸甘油酯、平平加、硬脂酸皂、吐温80、聚氧乙烯(2)硬脂醇醚、甲基葡萄糖苷倍半硬脂酸酯中的一种或多种。
优选的,所述油脂包括但不限于凡士林、羊毛脂、液体石蜡、蓖麻油、肉豆蔻酸异丙酯、角鲨烷、辛酸葵酸甘油三酯、蜂蜡、脂肪醇中的一种或多种。
与现有技术相比,本发明具有如下有益效果:
本发明采用特定的提取方法获得的雷公藤提取液、蜂房提取液和细辛提取液与木槿皮、土荆皮和南瓜子提取液协同增效,抑菌止痒效果显著,且无副作用。
本发明制备方法操作简单,制备的乳膏易涂抹、易展开,有利于有效成分的吸收。
具体实施方式
本发明提供了一种抑菌消炎止痒中药乳膏,包括如下重量份组分:雷公藤提取液1~5份、蜂房提取液3~10份、细辛提取液8~20份、木槿皮5~15份、土荆皮3~10份、南瓜子15~30份;优选的,雷公藤提取液2~4份、蜂房提取液5~8份、细辛提取液10~15份、木槿皮8~10份、土荆皮5~8份、南瓜子20~25份。在本发明中,若无特殊说明,所有的原料组分均为本领域技术人员熟知的市售商品。
在本发明中,所述雷公藤提取液的制备方法包括如下步骤:称取雷公藤粗粉,用75~95%的乙醇浸泡20~60min,回流提取3次;第一次加5~15倍水量,提取0.5~2.5h,过滤;第二次加5~15倍水量,提取0.5~2.5h,过滤;第三次加2~8倍水量,提取0.5~1.0h,过滤;合并三次过滤液,减压浓缩至初始体积的1/10~1/2,得雷公藤提取液。本发明所述雷公藤具有祛风除湿、活血通络、消肿止痛、杀虫、消炎、解毒的功效,属祛风湿药下分类的祛风湿强筋骨药。本发明所述的雷公藤提取液的制备方法可提取出抑菌和止痒的有效成分。
在本发明中,所述蜂房提取液的制备方法包括如下步骤:称取蜂房,于85~100℃加热水煎煮提取3次,第一次加10~25倍量水,提取1~3h,过滤;第二次加10~25倍量水,提取1~3h,过滤;第三次加5~10倍量水,提取0.5~1h,过滤,合并三次过滤液,减压浓缩至初始体积的1/10~1/2,得蜂房提取液。本发明所述蜂房具有祛风、攻毒、止痛的功效,属杀虫止痒药。本发明采用水提法可提取出消炎止痛的有效成分。
在本发明中,所述细辛提取液的制备方法包括如下步骤:称取细辛粉末,加水回流提取3次;第一次加5~15倍水量浸泡1.5~2.5h,回流提取2~4h,过滤;第二次加5~15倍水量浸泡1.5~2.5h,回流提取2~4h,过滤;第三次加2~8倍水量浸泡0.5~1.5h,回流提取1~2h,过滤;合并三次过滤液,减压浓缩至初始体积的1/10~1/2,得细辛提取液。本发明所述细辛具有祛风、散寒、通窍止痛、温肺祛痰的功效,属解表药下属分类的辛温解表药。本发明所述蒸馏水回流法可有效提取出祛风散寒的有效成分,协同所述其他药物发挥消炎止痒的功效。
在本发明中,所述木槿皮、土荆皮和南瓜子的处理方法包括:按照所述重量份比例称取木槿皮、土荆皮和南瓜子,混合粉碎,用5~15倍量的水浸泡20~60min,文火煎煮1~4h,过滤;于滤渣中加入5~15倍量的水,文火煎煮0.5~2.5h,过滤;合并两次过滤液,减压浓缩至初始体积的1/10~1/2,得木槿皮、土荆皮和南瓜子的提取液。本发明所述木槿皮具有清热利湿、杀虫止痒的功效,属杀虫止痒药;所述土荆皮具有祛风除湿、杀虫止痒、活血消肿的功效,属杀虫止痒药;所述南瓜子具有杀虫、下乳、利水消肿的功效,属利水渗湿药下属分类的利水消肿药。
本发明提供所述抑菌消炎止痒中药乳膏的制备方法,包括如下步骤:(1)将1~10份乳化剂、5~40份油脂置于干燥烧杯内,恒温水浴加热至70~90℃,使全部溶解成油相,备用;(2)将2~10份甘油、20~80份纯化水置另一烧杯中混匀成水相,恒温水浴加热至70~90℃,备用;(3)将油相缓缓加入水相中,搅拌均匀,均质3~15分钟,冷却降温即得乳膏基质;(4)按照所述重量份将雷公藤提取液,蜂房提取液,细辛提取液,木槿皮、土荆皮和南瓜子的提取液加入乳膏基质中,混合均匀,即得抑菌消炎止痒中药乳膏。本发明所述乳化剂包括但不限于单硬脂酸甘油酯、平平加、硬脂酸皂、吐温80、聚氧乙烯(2)硬脂醇醚、甲基葡萄糖苷倍半硬脂酸酯中的一种或多种,优选为单硬脂酸甘油酯、硬脂酸皂、吐温80、聚氧乙烯(2)硬脂醇醚中的一种,更优选为单硬脂酸甘油酯;所述油脂包括但不限于凡士林、羊毛脂、液体石蜡、蓖麻油、肉豆蔻酸异丙酯、角鲨烷、辛酸葵酸甘油三酯、蜂蜡、脂肪醇中的一种或多种,优选为液体石蜡、蓖麻油、肉豆蔻酸异丙酯、蜂蜡、脂肪醇中的一种,更优选为蓖麻油。本发明经该方法制备的乳膏易涂抹,易展开,易吸收,温和细腻,无刺激性,可有效抑菌和止痒。
下面将结合本发明中的实施例,对本发明中的技术方案进行清楚、完整地描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
该中药乳膏中含雷公藤提取液3份、蜂房提取液6份、细辛提取液15份、木槿皮10份、土荆皮6份、南瓜子24份。
雷公藤提取液的制备方法包括如下步骤:用85%的乙醇浸泡30min,回流提取3次;第一次加10倍水量,提取1.5h,过滤;第二次加10倍水量,提取1.5h,过滤;第三次加5倍水量,提取0.75h,过滤;合并三次过滤液,减压浓缩至初始体积的1/3,得雷公藤提取液,备用。
蜂房提取液的制备方法包括如下步骤:于95℃加热水煎煮提取3次,第一次加20倍量水,提取2h,过滤;第二次加15倍量水,提取2h,过滤;第三次加8倍量水,提取0.75h,过滤,合并三次过滤液,减压浓缩至初始体积的1/3,得蜂房提取液,备用。
细辛提取液的制备方法包括如下步骤:称取细辛粉末,加水回流提取3次;第一次加10倍水量浸泡2h,回流提取3h,过滤;第二次加10倍水量浸泡2h,回流提取3h,过滤;第三次加6倍水量浸泡1h,回流提取1.5h,过滤;合并三次过滤液,减压浓缩至初始体积的1/3,得细辛提取液,备用。
木槿皮、土荆皮和南瓜子的处理方法包括:按照所述重量份比例称取木槿皮、土荆皮和南瓜子,混合粉碎,用10倍量的水浸泡30min,文火煎煮2h,过滤;于滤渣中加入10倍量的水,文火煎煮2h,过滤;合并两次过滤液,减压浓缩至初始体积的1/3,得木槿皮、土荆皮和南瓜子的提取液。
中药乳膏的制备方法,包括如下步骤:
(1)将5份单硬脂酸甘油酯、30份蓖麻油置于干燥烧杯内,恒温水浴加热至75℃,使全部溶解成油相,备用;
(2)将9份甘油、30份纯化水置另一烧杯中混匀成水相,恒温水浴加热至75℃,备用;
(3)将油相缓缓加入水相中,均质10分钟,冷却降温即得乳膏基质。
(4)按照所述重量份将雷公藤提取液,蜂房提取液,细辛提取液,木槿皮、土荆皮和南瓜子的提取液依次加入乳膏基质中,混合均匀,即得抑菌消炎止痒中药乳膏。
实施例2
该中药乳膏中含雷公藤提取液5份、蜂房提取液10份、细辛提取液8份、木槿皮5份、土荆皮3份、南瓜子30份。
其余步骤与实施例1相同。
实施例3
该中药乳膏中含雷公藤提取液1份、蜂房提取液3份、细辛提取液18份、木槿皮13份、土荆皮10份、南瓜子15份。
其余步骤与实施例1相同。
对比例1
该中药乳膏中含细辛提取液15份、木槿皮10份、土荆皮6份、南瓜子24份。
制备步骤区别在于去除与雷公藤和蜂房相关的步骤,其余与实施例1相同。
对比例2
雷公藤提取液3份、木槿皮10份、土荆皮6份、南瓜子24份。
制备步骤区别在于去除与蜂房和细辛相关的步骤,其余与实施例1相同。
对比例3
该中药乳膏中含木槿皮10份、土荆皮6份、南瓜子24份。
制备步骤区别在于去除与雷公藤、蜂房和细辛相关的步骤,其余与实施例1相同。
实施例4
1、本发明中药乳膏的止痒评价实验
将正常小鼠随机分为空白组、模型对照组、中药乳膏剂组。给每组小鼠背部剃毛,剃毛部位和范围基本一致。将实施例1-3和对比例1-3制备的中药乳膏均匀涂于剃毛区皮肤上,作为中药乳膏剂组,空白对照组与模型对照组不涂任何膏剂,每组给药1次。给药后30min于中药乳膏剂组和模型对照组剃毛处皮下注射4-氨基吡啶1mg/kg,空白对照组注射等体积的生理盐水。记录各组动物在注射4-氨基吡啶后15min内舔体或抓挠反应的次数。结果见表1。由表1结果可知,本发明技术方案制备的中药乳膏可有效缓解皮肤瘙痒,且所用组分中任何一种或两种原料的舍弃均会降低对瘙痒症状抑制率,由此表明本发明选用的各中药组分具有协同作用。
表1各组小鼠的舔体或抓挠反应的次数
组别 | 舔体反应次数 | 抑制率 |
实施例1 | 7.3±1.7 | 84 |
实施例2 | 7.5±1.5 | 83.6 |
实施例3 | 7.6±1.3 | 83.3 |
对比例1 | 31.7±3.7 | 30.5 |
对比例2 | 29.4±4.2 | 35.5 |
对比例3 | 23.8±6.4 | 47.8 |
模型对照组 | 45.6±2.5 | --- |
空白对照组 | --- | --- |
2、本发明中药乳膏刺激性和过敏性试验
将10只小鼠背部去毛,每只小鼠在备注有两个去毛部位,去毛面积基本保持一致,在每只小鼠中的一个去毛部位分别涂抹实施例1~3制备的中药乳膏,另一个去毛部位不涂,和没涂部位进行比较,结果涂抹中药乳膏的部位与未涂抹相比无显著差异,即表明本发明中药乳膏没有刺激性和过敏反应。
从患有湿疹的患者中选取患病程度相当的志愿者20名,于患者患处涂抹适量实施例1~3制备的中药乳膏,过30分钟后观察,均没出现发红、发疹、起疱现象,志愿者表示涂抹完有清凉感,没有任何刺激性。
从正常人群中选取健康状态相当的志愿者10名,于志愿者手面涂抹适量实施例1~3制备的中药乳膏,过30分钟后观察,均没出现发红、发疹,起疱现象,志愿者表示涂抹完有清凉感,没有任何刺激性。
实施例5
本发明中药乳膏的应用案例
案例1:李某,男30岁,程序编辑员,屁股两侧以及内侧患有癣症,常反复发作,发作时常伴剧烈瘙痒,有时可波及到阴囊和阴茎,曾用曲安奈德益康唑乳膏,也使用过百川止痒液和过盐酸特比萘芬乳膏,仍旧反复瘙痒。让其停止治疗该病的任何药物的使用,使用本发明实施例1制备的中药乳膏,瘙痒剧烈一天3次,早中晚各一次,无明显瘙痒继续使用3天,一天2次,均匀涂抹在患处。患者陈述12小时后瘙痒症状缓解,1天后基本无瘙痒感,继续使用3天后湿疹消失,随访一年未复发。
案例2:谢某某,女2岁,脸部和四肢屈侧患有严重湿疹,并伴有剧烈瘙痒,使用地塞米松乳膏后,症状减缓,但是停药后,又开始瘙痒和起湿疹。让其停止治疗该病的任何药物的使用,使用本发明实施例1制备的中药乳膏,瘙痒剧烈一天2次,早晚各1次,无明显瘙痒继续使用2天,一天1~2次,均匀涂抹在患处。患者陈述6小时后瘙痒症状缓解,12小时后基本无瘙痒感,继续使用2天后湿疹消失,随访一年未复发。
案例3:张某,男75岁,诊断为老年性皮肤瘙痒,自觉全身瘙痒,以四肢最明显,夜间经常因瘙痒而醒,为阵发性,严重时为持续性瘙痒,阵发性加剧,有时难以忍耐。让其停止治疗该病的任何药物的使用,使用本发明实施例2制备的中药乳膏,瘙痒剧烈一天3次,早中晚各一次,无明显瘙痒继续使用3天,一天2次,均匀涂抹在患处。患者陈述12小时后瘙痒症状缓解,4天后基本无瘙痒感,继续使用3天后湿疹消失,随访一年未复发。
案例4:王某某,男27岁,脚趾中间以及脚两侧患有牛皮鲜,常反复发作,发作时常伴剧烈瘙痒,尤其夜间瘙痒的无法睡眠,使用维甲酸软膏,开始症状缓解,后又复方,再次使用,症状无法缓解。让其停止治疗该病的任何药物的使用,使用本发明实施例3制备的中药乳膏,瘙痒剧烈一天3次,早中晚各一次,无明显瘙痒继续使用3天,一天2次,均匀涂抹在患处。患者陈述24小时后瘙痒症状缓解,3天后基本无瘙痒感,继续使用3天后湿疹消失,随访一年未复发。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (9)
1.一种抑菌消炎止痒中药乳膏,其特征在于,包括如下重量份组分:雷公藤提取液1~5份、蜂房提取液3~10份、细辛提取液8~20份、木槿皮5~15份、土荆皮3~10份、南瓜子15~30份。
2.根据权利要求1所述的抑菌消炎止痒中药乳膏,其特征在于,包括如下重量份组分:雷公藤提取液2~4份、蜂房提取液5~8份、细辛提取液10~15份、木槿皮8~10份、土荆皮5~8份、南瓜子20~25份。
3.根据权利要求1所述的抑菌消炎止痒中药乳膏,其特征在于,所述雷公藤提取液的制备方法包括如下步骤:
称取雷公藤粗粉,用75~95%的乙醇浸泡20~60min,回流提取3次;第一次加5~15倍水量,提取0.5~2.5h,过滤;第二次加5~15倍水量,提取0.5~2.5h,过滤;第三次加2~8倍水量,提取0.5~1.0h,过滤;合并三次过滤液,减压浓缩至初始体积的1/10~1/2,得雷公藤提取液。
4.根据权利要求1所述的抑菌消炎止痒中药乳膏,其特征在于,所述蜂房提取液的制备方法包括如下步骤:
称取蜂房,于85~100℃加热水煎煮提取3次,第一次加10~25倍量水,提取1~3h,过滤;第二次加10~25倍量水,提取1~3h,过滤;第三次加5~10倍量水,提取0.5~1h,过滤,合并三次过滤液,减压浓缩至初始体积的1/10~1/2,得蜂房提取液。
5.根据权利要求1所述的抑菌消炎止痒中药乳膏,其特征在于,所述细辛提取液的制备方法包括如下步骤:
称取细辛粉末,加水回流提取3次;第一次加5~15倍水量浸泡1.5~2.5h,回流提取2~4h,过滤;第二次加5~15倍水量浸泡1.5~2.5h,回流提取2~4h,过滤;第三次加2~8倍水量浸泡0.5~1.5h,回流提取1~2h,过滤;合并三次过滤液,减压浓缩至初始体积的1/10~1/2,得细辛提取液。
6.根据权利要求1所述的抑菌消炎止痒中药乳膏,其特征在于,所述木槿皮、土荆皮和南瓜子的处理方法包括:按照所述重量份比例称取木槿皮、土荆皮和南瓜子,混合粉碎,用5~15倍量的水浸泡20~60min,文火煎煮1~4h,过滤;于滤渣中加入5~15倍量的水,文火煎煮0.5~2.5h,过滤;合并两次过滤液,减压浓缩至初始体积的1/10~1/2,得木槿皮、土荆皮和南瓜子的提取液。
7.根据权利要求1~6任意一项所述的抑菌消炎止痒中药乳膏的制备方法,其特征在于,包括如下步骤:
(1)将1~10份乳化剂、5~40份油脂置于干燥烧杯内,恒温水浴加热至70~90℃,使全部溶解成油相,备用;
(2)将2~10份甘油、20~80份纯化水置另一烧杯中混匀成水相,恒温水浴加热至70~90℃,备用;
(3)将油相缓缓加入水相中,搅拌均匀,均质3~15分钟,冷却降温即得乳膏基质;
(4)按照所述重量份将雷公藤提取液,蜂房提取液,细辛提取液,木槿皮、土荆皮和南瓜子的提取液加入乳膏基质中,混合均匀,即得抑菌消炎止痒中药乳膏。
8.根据权利要求7所述的抑菌消炎止痒中药乳膏的制备方法,其特征在于,所述乳化剂包括但不限于单硬脂酸甘油酯、平平加、硬脂酸皂、吐温80、聚氧乙烯(2)硬脂醇醚、甲基葡萄糖苷倍半硬脂酸酯中的一种或多种。
9.根据权利要求7所述的抑菌消炎止痒中药乳膏的制备方法,其特征在于,所述油脂包括但不限于凡士林、羊毛脂、液体石蜡、蓖麻油、肉豆蔻酸异丙酯、角鲨烷、辛酸葵酸甘油三酯、蜂蜡、脂肪醇中的一种或多种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211075614.7A CN116159086B (zh) | 2022-08-31 | 2022-08-31 | 一种抑菌消炎止痒中药乳膏及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211075614.7A CN116159086B (zh) | 2022-08-31 | 2022-08-31 | 一种抑菌消炎止痒中药乳膏及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116159086A true CN116159086A (zh) | 2023-05-26 |
CN116159086B CN116159086B (zh) | 2024-02-23 |
Family
ID=86416978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211075614.7A Active CN116159086B (zh) | 2022-08-31 | 2022-08-31 | 一种抑菌消炎止痒中药乳膏及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116159086B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103479842A (zh) * | 2013-09-25 | 2014-01-01 | 唐启裕 | 用于消肿止痛、活血散瘀、解毒止痒的中药 |
CN108578615A (zh) * | 2018-05-30 | 2018-09-28 | 武汉润禾生物医药有限公司 | 一种治疗瘙痒性皮肤病的抑菌软膏制备方法 |
-
2022
- 2022-08-31 CN CN202211075614.7A patent/CN116159086B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103479842A (zh) * | 2013-09-25 | 2014-01-01 | 唐启裕 | 用于消肿止痛、活血散瘀、解毒止痒的中药 |
CN108578615A (zh) * | 2018-05-30 | 2018-09-28 | 武汉润禾生物医药有限公司 | 一种治疗瘙痒性皮肤病的抑菌软膏制备方法 |
Non-Patent Citations (2)
Title |
---|
潘树伟, 李桂杰, 隋巧玲: "中医药治疗湿疹的临床进展", 中医药信息, no. 02, pages 12 - 13 * |
陈平;杨志波;杨光艳;颜纯钏;张红梅;: "外用中药治疗慢性湿疹研究进展", 中华中医药学刊, vol. 30, no. 3, pages 523 - 526 * |
Also Published As
Publication number | Publication date |
---|---|
CN116159086B (zh) | 2024-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109078165B (zh) | 一种用于女性私处护理的组合物及其制备方法与应用 | |
EP0621787A1 (en) | Skin therapeutic mixture containing cold-processed aloe vera extract, with yellow sap and aloin removed | |
CN108186711A (zh) | 促进伤口愈合的药物组合物 | |
CN108514572A (zh) | 一种抗炎和修复皮肤屏障的中药组合物、提取物及制剂 | |
US7205009B2 (en) | Composition for treating hair and scalp and method for preparing same | |
CN114146014B (zh) | 一种复方烟酸薄荷酯植物多糖乳膏及其制备方法 | |
WO2017080048A1 (zh) | 一种用于浅度烧伤的喷膜剂及其制备方法 | |
CN105943666B (zh) | 一种用于婴幼儿敏感肌肤护理的组合物及其制备方法 | |
CN116159086B (zh) | 一种抑菌消炎止痒中药乳膏及其制备方法 | |
CN103721138B (zh) | 一种治疗酒糟鼻的中药外用制剂及其制备方法 | |
CN110403998A (zh) | 一种抗痘与修复痘肌的组合物、中药提取物及中药制剂 | |
CN107158051B (zh) | 一种治疗湿疹的鞣酸软膏及其制备方法 | |
CN106963912B (zh) | 一种治疗湿疹的降香复方组合物及其制备方法 | |
CN102423342B (zh) | 防治皮肤湿疹和瘙痒症的药物组合物及剂型和应用 | |
JP6590233B1 (ja) | 皮膚疾患治療剤及びその製造方法 | |
CN110721274B (zh) | 一种外用止痒剂及其制备方法 | |
CN103920124B (zh) | 一种杀菌护肤冻疮膏 | |
CN108721442B (zh) | 治疗烧烫伤及尿布皮炎的中药组合物、制剂及其制备方法 | |
CN107536937B (zh) | 一种治疗皮肤病和灰指甲的外用中药药液及其制备方法 | |
CN111035684A (zh) | 一种臭氧油复方鼻炎凝胶及其制备方法 | |
CN106728069B (zh) | 一种治疗烫烧伤的祛腐生肌膏 | |
Viquar | Detoxification of the Therapeutically Essential Drug Aelwa (Aloe vera (L.) Burm. f.) Using a Modified Traditional Method | |
CN112999283A (zh) | 一种妇科用洗液及其制备方法 | |
CN116585404B (zh) | 一种治疗成人单纯性皮肤瘙痒症的外用中药组合物及制备方法 | |
CN107714834A (zh) | 一种山茶油外用制剂的组合物、制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |